BETAAccess all features while we're in beta! Some features may become paid later.Send feedback →
vpside

LRMR

Larimar Therapeutics, Inc.
Nasdaq · Pharmaceutical preparations (SIC 2834) · FY ends 31 Dec

Revenue, quarterly

$0
$1$0
Q2 ’15Q3 ’16Q4 ’17Q4 ’18Q1 ’20
Company filings · 10-Q filed 7 May 2020 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

—
Not reported in this company’s filings
Company filingsvpside.com

Cash and cash equivalents, quarter-end

$93M+350.2% year on year
$200M$100M$0
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 4 Aug 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

−$93M
$50M$0−$50M−$100M
Q3 ’20Q4 ’21Q1 ’23Q1 ’24Q2 ’25
Company filings · 10-Q filed 4 Aug 2026 · TTM = last four quartersvpside.com
Chart 05 is empty
Chart 06 is empty